Northern Trust Corp Purchases 38,155 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Northern Trust Corp raised its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 3.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,196,381 shares of the company’s stock after acquiring an additional 38,155 shares during the period. Northern Trust Corp owned approximately 0.80% of Xeris Biopharma worth $4,056,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of XERS. NewEdge Advisors LLC purchased a new stake in Xeris Biopharma during the fourth quarter valued at $34,000. R Squared Ltd purchased a new position in shares of Xeris Biopharma in the 4th quarter worth $42,000. Cibc World Markets Corp bought a new stake in shares of Xeris Biopharma in the 4th quarter worth about $44,000. Raymond James Financial Inc. purchased a new stake in shares of Xeris Biopharma during the 4th quarter valued at about $45,000. Finally, Aquatic Capital Management LLC purchased a new stake in shares of Xeris Biopharma during the 4th quarter valued at about $50,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Beth Hecht sold 40,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the transaction, the insider now owns 1,353,510 shares of the company’s stock, valued at $7,349,559.30. This represents a 2.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.47% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Oppenheimer lifted their price target on Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Friday, May 9th. Jefferies Financial Group reiterated a “buy” rating and issued a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Piper Sandler reissued a “neutral” rating and set a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Leerink Partners increased their price target on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, March 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Xeris Biopharma currently has an average rating of “Moderate Buy” and an average price target of $6.25.

Xeris Biopharma Price Performance

Shares of NASDAQ:XERS opened at $4.88 on Friday. The firm has a market capitalization of $763.16 million, a PE ratio of -10.84 and a beta of 1.10. The business has a 50 day simple moving average of $4.74 and a two-hundred day simple moving average of $3.95. Xeris Biopharma Holdings, Inc. has a 1 year low of $1.86 and a 1 year high of $6.07.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The business had revenue of $57.80 million during the quarter, compared to the consensus estimate of $57.61 million. Equities research analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.